{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:48:04Z","timestamp":1790920084756,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33 AI121627"],"award-info":[{"award-number":["R33 AI121627"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijpharm.2018.09.024","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T06:39:30Z","timestamp":1536907170000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"551","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yoon Kyung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2018.09.024_b0005","doi-asserted-by":"crossref","first-page":"e1020260","DOI":"10.1080\/21597081.2015.1020260","article-title":"Phage therapy of pulmonary infections","volume":"5","author":"Abedon","year":"2015","journal-title":"Bacteriophage"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12890-015-0062-7","article-title":"Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients","volume":"15","author":"Ahlgren","year":"2015","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0015","first-page":"1","article-title":"Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey","author":"Alves","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2018.01.010","article-title":"Nebulization effects on structural stability of bacteriophage PEV 44","author":"Astudillo","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0025","first-page":"1488","article-title":"The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator","volume":"54","author":"Bauer","year":"2009","journal-title":"Respiratory care"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","article-title":"Pseudomonas aeruginosa: all roads lead to resistance","volume":"19","author":"Breidenstein","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1098\/rspb.2001.1945","article-title":"Antagonistic coevolution between a bacterium and a bacteriophage","volume":"269","author":"Buckling","year":"2002","journal-title":"Proc. R. Soc. London B: Biol. Sci."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0040","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11095-017-2213-4","article-title":"Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, Jet Nebulizer, and Soft Mist Inhaler","volume":"34","author":"Carrigy","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/13543784.2017.1364728","article-title":"Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis","volume":"26","author":"Cartlidge","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0050","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0055","first-page":"01714","article-title":"Anti-Pseudomonal activity of phage PEV20 in a dry powder formulation\u2014a proof-of-principle study in a murine lung infection model","volume":"AAC","author":"Chang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0060","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-17","article-title":"Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation","volume":"62","author":"Chang","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2018.08.001","article-title":"Phage therapy for respiratory infections","author":"Chang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.09.002","article-title":"Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection","volume":"121","author":"Chang","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168615","article-title":"Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms","volume":"12","author":"Chaudhry","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0080","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","article-title":"Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth","volume":"2","author":"Comeau","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0085","doi-asserted-by":"crossref","first-page":"28115","DOI":"10.1038\/srep28115","article-title":"A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections","volume":"6","author":"Danis-Wlodarczyk","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jamp.2008.0701","article-title":"Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex","volume":"21","author":"Golshahi","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Delivery"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0095","first-page":"3653","article-title":"Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status","volume":"9","author":"Hraiech","year":"2015","journal-title":"Drug Des. Dev. Therapy"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0100","series-title":"Advances in Applied Microbiology","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","article-title":"Bacteriophage host range and bacterial resistance","author":"Hyman","year":"2010"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/AEM.02850-14","article-title":"Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity","volume":"81","author":"Kamal","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0110","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1136\/thx.52.2008.S92","article-title":"Selecting and using nebuliser equipment","volume":"52","author":"Kendrick","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.ijpharm.2018.09.024_b0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.resmic.2012.08.008","article-title":"Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa","volume":"164","author":"Knezevic","year":"2013","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0125","first-page":"e01965","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic modeling of aerosolized colistin in a mouse lung infection model","volume":"62","author":"Lin","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/crj.12787","article-title":"Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010\u20132013)","author":"Lucca","year":"2018","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0135","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/593186","article-title":"Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease","volume":"47","author":"Mart\u00ednez-Solano","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2018.04.010","article-title":"Delivering drugs to the lungs: the history of repurposing in the treatment of respiratory diseases","author":"Newman","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajme.2015.05.002","article-title":"Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa","volume":"52","author":"Nouraldin","year":"2016","journal-title":"Alexandria J. Med."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0150","first-page":"703","article-title":"Synergistic interaction between phage therapy and antibiotics clears pseudomonas aeruginosa infection in endocarditis and reduces virulence","volume":"215","author":"Oechslin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0155","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.2042-7158.2011.01324.x","article-title":"Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy","volume":"63","author":"Ryan","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0160","first-page":"395","article-title":"Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro","volume":"65","author":"Ryan","year":"2012","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrmicro1793","article-title":"CRISPR\u2014a widespread system that provides acquired resistance against phages in bacteria and archaea","volume":"6","author":"Sorek","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tim.2015.12.011","article-title":"Evolutionary rationale for phages as complements of antibiotics","volume":"24","author":"Torres-Barcel\u00f3","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0175","first-page":"1","article-title":"Piperacillin and ceftazidime produce the strongest synergistic phage\u2013antibiotic effect in Pseudomonas aeruginosa","author":"Uchiyama","year":"2018","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2014.11.004","article-title":"Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead","volume":"85","author":"Velkov","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ijpharm.2018.09.024_b0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/02786826.2016.1262532","article-title":"Examining the ability of empirical correlations to predict subject specific in vivo extrathoracic aerosol deposition during tidal breathing","volume":"51","author":"Yang","year":"2017","journal-title":"Aerosol Sci. Technol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318306756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318306756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T09:55:36Z","timestamp":1662026136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517318306756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0378517318306756"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.024","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}